HanchorBio Founder and Chief Executive Officer Dr. Scott Liu Receives Award from Chinese-American Biopharmaceutical Society 漢康生技創始人兼執行長 劉世高博士榮獲 北美華人生物醫藥協會2022年度方瑞賢生命科學獎

HanchorBio Inc., a global biotechnology company developing innovative immuno-medicines, today announced that Dr. Scott Liu, Founder, Chairman, and CEO of HanchorBio Inc., received the CABS Kenneth Fong Award in Life Sciences for the outstanding contribution to the development of multiple biologic products from research to launch from the Chinese-American Biopharmaceutical Society (CABS).

“I am honored to receive this recognition from CABS,” said Dr. Scott Liu. “I have dedicated my career to bringing better, safer, and affordable treatment for patients who are battling against cancer. I look forward to furthering this mission at HanchorBio to fulfill the unmet needs that still exist for many cancer patients.”

Founded HanchorBio in December 2020, Dr. Liu was one of the global partners of Fosun International Limited and the Co-Founder, President, and CEO of Shanghai Henlius Biotech Inc., a commercial-stage global biopharmaceutical company with the focus on high-quality, affordable, and innovative biologic medicines, where he led over 30 product initiatives and successfully launched 5 commercial products in China and Europe. Today, at HanchorBio, Dr. Liu oversees a robust pipeline from the proprietary Fc-based designer biologics (FBDB™) platform developed in-house, which enables unique biologics with diverse multi-targeting modalities. A unique feature of the FBDB projects is to re-engage innate and adaptive immunity through multifunctional designs to overcome the inadequacies of anti-PD1/L1 therapies and increase the ORR and OS for patients suffering from various types of hematological and solid malignancies.

Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States. 

The CABS Kenneth Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality-of-life. Candidates must be nominated by an active member of CABS. Selection criteria will be based on candidate’s accomplishments in life sciences and contribution to the life science community. Past 3 recipients of CABS K. Fong Awards:

2021 – Dr. Xian-Ping Lu, Chairman, CEO of Shenzhen Chipscreen Biosciences, for his entrepreneurship in building Chipscreen into a leading Chinese drug discovery and development company

2020 – Dr. John Link, Former VP of Chemistry at Gilead Sciences, for his scientific leadership in the discovery of ledipasvir and velpatasvir (Harvoni® Epclusa®)

2019 – Dr. John Oyler, Chairman, Co-Founder and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company

About Dr. Kenneth Fong
Dr. Fong has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research. He is best known for founding Clontech, a biotech company in 1984, where he had cultivated it to be one of the largest biomedical tool companies founded by an Asian American in the US (400 people with 65 PhD scientists). Clontech was sold to Becton Dickson in 1999 and Ken has continued his career as Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them, and working with them on the growth of their companies. He currently sits on the board of 4 biotech companies, and he was intimately involved with M&A and IPO of more than 10 companies that are worth north of $3 billion. For more information on CABS, please visit: www.cabsweb.org 


       2022年11月12日--專注於研發創新腫瘤免疫治療藥物的全球性生物技術公司——漢康生技,今天宣佈,漢康生技的創始人、董事長兼執行長 劉世高博士榮獲北美華人生物醫藥協會(CABS)頒發的 "2022年度方瑞賢生命科學獎",以表彰其對多種生物製藥從研發到上市階段所做出的傑出貢獻。

      "我很榮幸獲得北美華人生物醫藥協會的認可,"劉博士說,"我的職業生涯始終致力於 為與癌症作鬥爭的患者帶來更好、更安全、更可負擔的治療藥物而努力。我期待著在漢康生技進一步完成這一使命,以滿足眾多癌症患者未滿足的臨床需求。"

       劉博士於2020年12月創立了漢康生技,他曾是復星國際有限公司的全球合夥人之一,也是上海複宏漢霖生物技術有限公司的聯合創始人之一、總裁兼執行長,複宏漢霖是一家處於藥品商業化階段的全球生物製藥公司,專注于開發高品質、並可負擔的生物製藥,他領導了30多個產品的開發計畫,並在中國和歐洲成功推出了5種商業化產品。如今,在漢康生技,劉博士領導公司團隊開發出一種基於Fc具特殊設計構型的多功能創新生物藥開發平臺(FBDB™)。通過該平臺能夠開發出具有多種靶向模式的生物產品,可同時釋放先天性免疫系統和適應性免疫系統的潛力,以克服現有抗PD-1/L1療法所遇到的挑戰,並提高各類血液瘤和實體瘤患者的總體回應率及總體存活率。

       北美華人生物醫藥協會(CABS)組織的第23屆太平洋生物大會於2022年11月12日舉辦,此次會議主題為 "韌性與創新--迎接新常態下的機遇"。今年的主題反映了儘管在新冠疫情仍未結束的大背景下,經濟和供應鏈持續動盪,但對生命科學和生物製藥行業來說,這既是新的挑戰,也是新的機遇。方瑞賢生命科學獎的頒獎環節為本次大會的一部分。在過去的24年裡,CABS一直是美國西部最大和最活躍的面向生物製藥行業專業人士的非盈利組織之一。在生命科學行業擁有超過3000名會員,其中70%的成員擁有與生命科學相關的博士學位。其中相當一部分成員在美國和跨國生物科學公司擔任高級研究和管理職位。 

       方瑞賢生命科學獎是一項年度獎項,由北美華人生物醫藥協會(CABS)每年頒發一次,以表彰那些在生命科學和生物製藥行業做出重大貢獻的個人,其中包括以下一項或全部內容:包括傑出的科學發現,在促進生命科學教育和改善生命科學社區的舉措方面做出的公認努力,以及那些將突破性療法推向市場並改善醫療保健和提高生活品質的人。候選人必須由CABS的一位活躍成員提名。評選標準是基於候選人在生命科學領域的成就和對生命科學界的貢獻。過去3年的方瑞賢生命科學獎獲得者是:

2021年—魯先平博士,深圳微芯生物科技股份有限公司創始人、董事長兼執行長,表彰他以企業家精神將微芯生物打造成中國領先的藥物發現和開發公司。

2020年--約翰-林克博士,吉利德公司前化學副總裁,表彰他在發現雷迪帕韋和維帕他韋(Harvoni® Epclusa®)方面的科學領導能力。

2019年--約翰-奧勒博士,百濟神州有限公司董事長、聯合創始人兼執行長,表彰他以企業家精神和卓越的商業領導力將百濟神州有限公司打造為世界級的生物製藥公司。


關於方瑞賢博士
      在完成生物醫學學術研究後,方博士在過去32年裡一直從事生物技術行業。他最著名的成就是在1984年創立了生物技術公司Clontech,並將其發展成美國最大的由亞裔美國人創立的生物公司之一(400名員工,65名博士科學家)。Clontech在1999年被出售給了Becton Dickson,而方博士則繼續他的事業,成為他所創立的Kenson Ventures的風險投資人。此後,他培養了10多位非常成功的企業家,為他們提供建議,並與他們一起為他們的公司發展而努力。他目前是4家生物技術公司的董事會成員,並密切參與了10多家公司的並購和IPO,這些公司的價值在30億美元以上。
關於CABS的更多資訊,請訪問:www.cabsweb.org